News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEvents
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Jack Kain, PharmD

Advertisement

Articles by Jack Kain, PharmD

Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

ByJack Kain, PharmD
June 16th 2022

Although the CDC has put forth a strong effort to improve its opioid guidelines, many providers still feel that more can be done.

Advertisement

Latest Updated Articles

  • Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?
    Does the CDC’s Proposed Opioid Prescribing Guideline Fall Short on Drug Testing?

    Published: June 16th 2022 | Updated:



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Managing Acute and Late Adverse Effects of Breast Cancer Radiation

2

An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team

3

Improving Access to Supportive Care on an Organizational Level With Korie Bigbee

4

Osimertinib/Chemo Boosts OS in EGFR+ NSCLC With Poor Prognosis

5

Solo Sevabertinib Shows Durable Activity in HER2+ NSCLC

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us